Email

enquiries@lvcthealth.org

Phone

T: + 254 722 203610

Web

https://lvcthealth.org/

Address

Sonning Suites, Suna Road, Off Ngong Road, Nairobi 00202
About LVCT Health

LVCT Health is an established Kenyan NGO registered in 2002 that is renowned for the implementation of health programs at scale in Kenya and beyond. Through our vision of Empowered, Healthy and Resilient Communities, we remain a leader in designing and implementing innovative health programs in the areas of HIV, sexual and reproductive health, maternal and child health, sexual violence prevention, mental health, and health systems strengthening.

LVCT Health participated in the development of key guidelines in Kenya
1. Kenya National Guidelines for Management and Control of STIs 2018
2. Kenya guidelines on control and management of viral hepatitis 2019
Currently they are also supporting the review of these guidelines

  • LVCT Health provided technical expertise to the development of the Kenyan clinical guidelines on screening, prevention and management of viral hepatitis
    ● Championed for the inclusion of hepatitis B and C in two national guidelines; Guidelines on prevention & management of HIV and Guidelines on control and prevention of STI.
    ● Participated in the country level pilot of the Gilead drug Harvoni for the treatment of hepatitis C infection. The oral drug is administered orally for a period of 12 weeks with a cure rate of up to 90%.
    ● Implementation of large and to scale projects targeting key populations, persons living with HIV, sexual minorities, priority populations and general population including women.
    ● Have existence in 33 out of 47 counties on direct service delivery and implementation
    ● Run an innovative digital health program with a One2One stepped care model that has a free hotline (1190) which uses SMS & calls and an interactive website and social media platforms like X formerly Twitter, Youtube, Facebook and Instagram. This platform helps to provide information and education to people in Kenya and beyond. We anticipate to leverage on these existing structures to increase awareness for viral hepatitis
    ● LVCT Health currently provides direct service delivery to 278,04 (21%) of the 1,355,301 PLHIV in Kenya. Through our existing programs in 13 counties of Mombasa, Kilifi, Kwale, Taita Taveta, Lamu, Kiambu, Muranga, Nyeri, Kirinyaga, Embu, Tharaka Nithi, Homabay and Kisii, it will be easier to reach pregnant women, children and key population.
    ● We also are supporting the USAID counties of Nairobi, Nakuru, Kisumu, Bungoma, Busia, Kakamega, Meru, Turkana, Mombasa, Kilifi through the MiCARE project works in 10 USAID-supported counties for Key and Vulnerable Population programs. We work with a total 18 Local Implementing partners, 27 DiCEs and 49 KP integrated Ministry of Health facilities to increase access to mental health care for the Gender and Sexual Minority (GSM) community.
    ● Provided comprehensive harm reduction package for PWUD including programming for viral hepatitis.
    ● Good collaboration with the government and Ministry of Health through various divisions including NASCOP and NVIP.
    ● Over the last 4 years, within a Centre for Disease Control & Prevention (CDC) funded project dubbed STAR aimed at strengthening HIV/AIDS and Tuberculosis response within the Kenya Prisons, LVCT Health has supported in managing viral hepatitis through support of testing commodities, prevention and management of outbreaks.
    ● Currently working in a collaborative grant with CGHE/TFGH to facilitate introduction of hepatitis B birth dose vaccination advocacy in Kenya

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close